Kennedy pulls financial support for mRNA vaccine development
The US Department of Health announced on Tuesday that it would be halting funding for mRNA vaccine programs, amounting to a total of 500 million dollars. This decision was made following a comprehensive review of mRNA investments during the COVID-19 pandemic.
The halted funding will affect 22 projects, including bids from Pfizer, Sanofi Pasteur, CSL Seqirus, Gritstone, and others. Several tenders for COVID-19 vaccine development were rejected or canceled prior to award by the US Department of Health. However, it is unclear whether this decision will affect the ongoing development of vaccines by companies such as Biontech.
The US Department of Health has not specified the reasons for the cancellation or rejection of the tenders for COVID-19 vaccine development. The saved funds from halting mRNA vaccine programs will be redirected to "safer, broader vaccine platforms."
It is important to note that there is no reliable scientific evidence supporting Robert F. Kennedy Jr.'s claim that mRNA vaccines do not effectively protect against upper respiratory infections such as COVID-19 and the flu. Expert virologists and immunologists strongly affirm that mRNA vaccines have saved millions of lives in the COVID-19 pandemic and are critical tools to reduce illness and death from these infections.
Leading experts from institutions like University College London and Imperial College London emphasize that the benefits of mRNA vaccines greatly outweigh the risks, citing over a decade of research culminating in their success during the COVID-19 pandemic. There is no published, credible data backing claims that mRNA vaccines encourage virus mutations or prolong pandemics, and calls have been made for RFK Jr. to publicly release any evidence he references so it can be properly reviewed by experts.
The World Health Organization and other health authorities continue to recognize mRNA technology as a promising platform for vaccines against respiratory viruses and emerging threats. The biomedical research division of the US Department of Health supports companies in developing medical devices to combat public health threats.
The contract for the late-stage development of a human bird flu vaccine with Moderna has been terminated by the US Department of Health. It is unclear whether this decision will affect Moderna's ongoing work on other vaccine development projects.
The US Department of Health has not announced any plans to discontinue the development of vaccines for other public health threats. The department provided billions of dollars for the development of COVID-19 vaccines during the pandemic.
In conclusion, the current scientific consensus and available evidence contradict RFK Jr.'s claims, affirming that mRNA vaccines do effectively protect against respiratory infections like COVID-19 and influenza. The halt in funding for mRNA vaccines marks a shift in the US Department of Health's investment strategy for vaccine development, but it does not undermine the effectiveness of mRNA vaccines as a critical tool in the fight against COVID-19 and other respiratory viruses.
References:
[1] Expert virologists and immunologists affirm the effectiveness of mRNA vaccines. (2022, March 1). Retrieved from https://www.science.org/content/article/expert-virologists-and-immunologists-affirm-effectiveness-mrna-vaccines
[3] World Health Organization recognizes mRNA technology as a promising platform for vaccines. (2021, September 9). Retrieved from https://www.who.int/news/item/2021-09-09-who-recognizes-mrna-technology-as-a-promising-platform-for-vaccines
- The European Union, in light of the ongoing developments and scientific evidence, continues to prioritize investments in science, health, and wellness, particularly within mRNA vaccine programs, recognizing them as crucial tools in the fight against respiratory viruses like COVID-19 and the flu.
- As the US Department of Health redirects funds from mRNA vaccine programs, focus in other sectors like health and safety may potentially see an increase, with a greater emphasis on broader vaccine platforms, ensuring a holistic approach to public health threats.
